Kyn Therapeutics Appoints Douglas Carlson as Chief Financial Officer
Collegium Pharmaceutical, Inc. (COLL)
Last collegium pharmaceutical, inc. earnings: 2/27 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.collegiumpharma.com
Company Research
Source: Business Wire
BOSTON--(BUSINESS WIRE)-- Kyn Therapeutics, a clinical-stage biotechnology company developing new immunometabolic therapies for treating cancer, today announced that it is expanding its management team with the appointment of Douglas Carlson as its chief financial officer. Mr. Carlson’s most recent role was vice president, commercial operations, corporate strategy & business development at Collegium Pharmaceutical (NASDAQ:COLL), a specialty pharmaceutical company focused on pain management. “Doug brings nearly two decades of multi-disciplinary experience in the strategic financial management of biotech and healthcare companies. He joins Kyn at a new stage of its growth with the initiation of our EP4 antagonist clinical program and the signing of our global strategic collaboration with Celgene on two other immuno-oncology programs,” said Mark Manfredi, Ph.D., Kyn’s president and chief executive officer.
Show less
Read more
Impact Snapshot
Event Time:
COLL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
COLL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
COLL alerts
High impacting Collegium Pharmaceutical, Inc. news events
Weekly update
A roundup of the hottest topics
COLL
News
- Collegium Pharmaceutical, Inc. (NASDAQ: COLL) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.MarketBeat
- Are Investors Undervaluing Collegium Pharmaceutical (COLL) Right Now? [Yahoo! Finance]Yahoo! Finance
- Zacks.com featured highlights AppLovin, Kaiser Aluminum, Collegium Pharmaceutical, EMCOR Group and Textron [Yahoo! Finance]Yahoo! Finance
- 3 Reasons Why Collegium Pharmaceutical (COLL) Is a Great Growth Stock [Yahoo! Finance]Yahoo! Finance
- Thinking about buying stock in BigBear.ai, Supernus Pharmaceuticals, Collegium Pharmaceutical, Duolingo, or Cryptoblox Technologies?PR Newswire
COLL
Earnings
- 2/22/24 - Beat
COLL
Sec Filings
- 3/4/24 - Form 4
- 2/29/24 - Form 144
- 2/28/24 - Form 4
- COLL's page on the SEC website